[go: up one dir, main page]

MX2009008951A - Microesferas que comprenden una matriz de sustancia activa y un revestimiento polimerico, y un metodo para producir dichas microesferas. - Google Patents

Microesferas que comprenden una matriz de sustancia activa y un revestimiento polimerico, y un metodo para producir dichas microesferas.

Info

Publication number
MX2009008951A
MX2009008951A MX2009008951A MX2009008951A MX2009008951A MX 2009008951 A MX2009008951 A MX 2009008951A MX 2009008951 A MX2009008951 A MX 2009008951A MX 2009008951 A MX2009008951 A MX 2009008951A MX 2009008951 A MX2009008951 A MX 2009008951A
Authority
MX
Mexico
Prior art keywords
pellets
active substance
polymer coating
polymer
producing
Prior art date
Application number
MX2009008951A
Other languages
English (en)
Inventor
Hans-Ulrich Petereit
Christian Meier
Kathrin Nollenberger
Andreas Gryczke
Christian Brunnengraber
Andreas Klosendorf
Reinhard Menzel
Original Assignee
Evonik Roehm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm Gmbh filed Critical Evonik Roehm Gmbh
Publication of MX2009008951A publication Critical patent/MX2009008951A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención trata de microesferas que contienen compuesto activo que tienen un revestimiento polimérico y un tamaño de partícula promedio que varía entre 300 a 1100 pm, que comprende una sustancia farmacéuticamente activa, incrustada en una matriz polimérica de uno o más polímeros que se caracterizan porque las microesferas tienen una friabilidad de máximo 0.1 %, medida utilizando 200 g de microesferas en una máquina cribadora que tiene un tamiz de 200 pm, un diámetro de tamiz de 20 cm y 1.5 mm de amplitud de agitación en una frecuencia de agitación de 50 1/segundos durante 10 minutos en la presencia de seis cubos de goma que tienen longitud de borde de 1.8 cm y se recubren con un revestimiento polimérico de un copolímero de metacrilato aniónico, con la condición de que las microesferas no liberan más del 10% del compuesto activo contenido en la prueba de liberación de acuerdo con USP en el jugo gástrico artificial que tiene pH 1.2 después de 120 minutos.
MX2009008951A 2007-02-22 2007-11-21 Microesferas que comprenden una matriz de sustancia activa y un revestimiento polimerico, y un metodo para producir dichas microesferas. MX2009008951A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007009243A DE102007009243A1 (de) 2007-02-22 2007-02-22 Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
PCT/EP2007/062603 WO2008101554A1 (de) 2007-02-22 2007-11-21 Pellets mit einer wirkstoff-matrix und einem polymerüberzug, sowie ein verfahren zur herstellung der pellets

Publications (1)

Publication Number Publication Date
MX2009008951A true MX2009008951A (es) 2009-08-31

Family

ID=38983907

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008951A MX2009008951A (es) 2007-02-22 2007-11-21 Microesferas que comprenden una matriz de sustancia activa y un revestimiento polimerico, y un metodo para producir dichas microesferas.

Country Status (11)

Country Link
US (1) US20080206324A1 (es)
EP (1) EP2120955A1 (es)
JP (1) JP5345557B2 (es)
KR (1) KR101465819B1 (es)
CN (1) CN101626769A (es)
BR (1) BRPI0721369A2 (es)
CA (1) CA2677727A1 (es)
DE (1) DE102007009243A1 (es)
IL (1) IL199817A0 (es)
MX (1) MX2009008951A (es)
WO (1) WO2008101554A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
EP2227225B1 (en) * 2008-01-10 2018-11-14 Evonik Röhm GmbH Coated pharmaceutical or nutraceutical preparation with enhanced pulsed active substance release
HUE034848T2 (en) * 2008-01-10 2018-03-28 Evonik Roehm Gmbh Coated pharmaceutical or nutraceutical preparation with enhanced active substance release in the colon
KR20100103565A (ko) * 2008-01-10 2010-09-27 에보니크 룀 게엠베하 촉진되고 조절된 활성 물질 방출을 갖는 코팅된 제약학적 또는 건강기능성 제제
EA021792B1 (ru) 2008-03-11 2015-09-30 Такеда Фармасьютикал Компани Лимитед Твердый препарат, растворяющийся во рту
SMT201700601T1 (it) 2009-04-03 2018-03-08 Ocera Therapeutics Inc L-ornitina fenilacetato e metodi per la sua fabbricazione
CN101897674B (zh) * 2009-05-25 2012-12-19 范敏华 L-半胱氨酸片及其制备方法
MX2011013129A (es) 2009-06-08 2012-03-14 Ucl Business Plc Tratamiento de hipertension portal y restauracion de la funcion hepatica usando fenilacetato de l-ornitina.
WO2011126733A2 (en) * 2010-03-28 2011-10-13 Children's Medical Center Corporation Combination therapies: inhibitors of gaba transaminase and nkcc1
ITPN20100027A1 (it) * 2010-05-12 2011-11-13 Friulchem S P A Processo per la preparazione di cilindri e granuli utilizzabili nell'industria veterinaria e mangimistica contenenti principi farmacologicamente attivi, integratori, nutrienti, vitamine o microorganismi
CN101961324A (zh) * 2010-09-10 2011-02-02 武汉药谷生物工程有限公司 一种依托贝特缓释胶囊的处方及制备方法
CN103154056B (zh) * 2010-10-13 2016-03-23 赢创罗姆有限公司 通过在溶液中的自由基聚合制备含季铵基的（甲基）丙烯酸酯共聚物的方法
CN102258478B (zh) * 2011-04-29 2013-02-27 武汉华扬动物药业有限责任公司 一种兽用甲磺酸培氟沙星微丸及其制备方法
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
HK1252003A1 (zh) 2015-05-04 2019-05-10 Confluence Pharmaceuticals, Llc 阿坎酸散剂
HUE052340T2 (hu) 2015-06-05 2021-05-28 Evonik Operations Gmbh Gyógyszer- vagy tápkészítmény etanol hatása elleni ellenállóképességgel
CN104983692A (zh) * 2015-07-17 2015-10-21 江西博莱大药厂有限公司 一种阿莫西林缓释微丸及其制备方法
RU2018113801A (ru) * 2015-11-13 2019-12-16 Осера Терапьютикс, Инк. Составы l-орнитин фенилацетата
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
EP3624788A4 (en) 2017-05-17 2021-03-03 Confluence Pharmaceuticals, LLC FORMULATIONS OF HOMOTAURINS AND THEIR SALTS
CN108338978B (zh) * 2018-04-20 2020-09-18 广州白云山医药集团股份有限公司白云山制药总厂 一种s-羧甲基-l-半胱氨酸肠溶微丸胶囊
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
JP7560483B2 (ja) * 2019-05-15 2024-10-02 エボニック オペレーションズ ゲーエムベーハー カプセル充填機を用いて、（メタ）アクリレートコポリマー系のコーティングを有する、充填されたハードシェルカプセルを製造する方法
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US10792262B1 (en) * 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2135073C3 (de) 1971-07-14 1974-07-11 Roehm Gmbh Überzugsmittel für Arzneiformen
DE3106449A1 (de) 1981-02-20 1982-09-09 Röhm GmbH, 6100 Darmstadt "in magensaft loesliche oder quellbare ueberzugsmasse und ihre verwendung in einem verfahren zum ueberziehen von arzneiformen"
EP0164669B1 (de) 1984-06-13 1991-01-23 Röhm Gmbh Verfahren zum Überziehen von Arzneiformen
DE3438291A1 (de) 1984-10-19 1986-04-24 Röhm GmbH, 6100 Darmstadt Verfahren zur herstellung einer waessrigen ueberzugsmitteldispersion und ihre verwendung zum ueberziehen von arzneimitteln
JP2536876B2 (ja) * 1987-07-31 1996-09-25 寛治 高田 シクロスポリンの溶解性粉末状製剤
JP2542122B2 (ja) * 1990-04-18 1996-10-09 旭化成工業株式会社 球状核、球形顆粒およびその製造方法
TW209174B (es) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
DE9414065U1 (de) 1994-08-31 1994-11-03 Röhm GmbH & Co. KG, 64293 Darmstadt Thermoplastischer Kunststoff für darmsaftlösliche Arznei-Umhüllungen
DE9414066U1 (de) 1994-08-31 1994-11-03 Röhm GmbH & Co. KG, 64293 Darmstadt Überzugs- und Bindemittel für Arzneiformen sowie damit hergestellte Arzneiform
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
PL188919B1 (pl) * 1996-03-08 2005-05-31 Nycomed Danmark As Doustna, multijednostkowa kompozycja preparatu farmaceutycznego o modyfikowanym uwalnianiu oraz sposób wytwarzania jednostki dawkowania doustnej multijednostkowej kompozycji farmaceutycznej o modyfikowanym uwalnianiu
DE10011447A1 (de) 2000-03-10 2001-09-20 Roehm Gmbh Dispersion mit nichtionischem Emulgator
DE10013029A1 (de) 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
JP2001270821A (ja) * 2000-03-23 2001-10-02 Eisai Co Ltd 服用感が優れた散剤
WO2002035991A2 (en) * 2000-10-30 2002-05-10 The Board Of Regents, The University Of Texas System Spherical particles produced by a hot-melt extrusion/spheronization process
DE10208335A1 (de) 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
DE10250543A1 (de) * 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
MXPA04010956A (es) * 2003-01-30 2005-01-25 Roehm Gmbh Forma de dosis farmaceutica y metodo para la produccion de la misma.
US20050106253A1 (en) * 2003-11-13 2005-05-19 Platteeuw Johannes J. Pharmaceutical pellets comprising tamsulosin
CN1909889B (zh) * 2004-01-09 2010-06-02 韩美药品株式会社 头孢呋辛酯颗粒及其制备方法
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
DE102004007713A1 (de) 2004-02-16 2005-09-01 Leistritz Extrusionstechnik Gmbh Vorrichtung zur Herstellung gerundeter Pellets
DE102004011349A1 (de) 2004-03-05 2005-09-22 Basf Ag Wässrige Polymerdispersion auf Basis von Alkyl(meth)-acrylaten
DE102004027924A1 (de) * 2004-06-09 2005-12-29 Röhm GmbH & Co. KG Arzneiform, enthaltend den Wirkstoff Cholylsarcosin
JP2008505124A (ja) * 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
US20070178149A1 (en) * 2005-11-07 2007-08-02 Moshe Flashner-Barak Levodopa compositions
US20090324717A1 (en) * 2006-07-28 2009-12-31 Farmaprojects, S. A. Extended release pharmaceutical formulation of metoprolol and process for its preparation
CN101484147B (zh) * 2006-08-18 2015-07-08 赢创罗姆有限责任公司 对于具有水中良好溶解性的活性成分具有受控的活性成分释放性的药物组合物
DE102007009242A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix

Also Published As

Publication number Publication date
BRPI0721369A2 (pt) 2014-03-04
JP2010519228A (ja) 2010-06-03
CN101626769A (zh) 2010-01-13
EP2120955A1 (de) 2009-11-25
WO2008101554A1 (de) 2008-08-28
KR20090112718A (ko) 2009-10-28
US20080206324A1 (en) 2008-08-28
JP5345557B2 (ja) 2013-11-20
DE102007009243A1 (de) 2008-09-18
CA2677727A1 (en) 2008-08-28
KR101465819B1 (ko) 2014-11-27
IL199817A0 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
MX2009008951A (es) Microesferas que comprenden una matriz de sustancia activa y un revestimiento polimerico, y un metodo para producir dichas microesferas.
MX2009008952A (es) Microesferas que comprenden una matriz de sustancia activa resistente a jugo gastrico.
Işıklan et al. pH responsive itaconic acid grafted alginate microspheres for the controlled release of nifedipine
CA2624372C (fr) Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
WO2007006353A3 (de) Verwendung eines teilneutralisierten, anionischen (meth) acrylat-copolymers als uberzug fur die herstellung einer arzneiform mit einer wirkstofffreisetzung bei erniedrigten ph-werten
CA2360655A1 (en) Pharmaceutical compositions
EP2389928A3 (en) Biodegradable polymer encapsulated microsphere particulate film and method of making thereof
MY169471A (en) Controlled release preparation
WO2002002745A3 (en) Method and system for consistent and effective encapsulation of biological material
RU2013111605A (ru) Резистентная к действию желудочного сока фармацевтическая или нутрицевтическая композиция, содержащая одну или более солей альгиновой кислоты
JP2004531399A5 (es)
EP1493455A3 (en) Crosslinked polymeric composite for orthopaedic implants
TW201718365A (zh) 高透濕性多微孔塑膠薄膜及其製造方法、以及製造裝置
Elsergany et al. Influence of the porosity of cushioning excipients on the compaction of coated multi-particulates
CN109316466A (zh) 一种盐酸普拉克索缓释制剂及其制备方法
WO2006006035A3 (en) A safe delivery system for agriculturally active material
US7445796B2 (en) Pharmaceutically active particles of a monomodal particle size distribution and method
Patil et al. Natural binders in tablet formulation
WO2007010584A3 (en) Controlled-delivery system of pharmacologically active substances, preparation process and medical use thereof
WO2005123045A3 (en) Controlled release matrix pharmaceutical dosage formulation
US20130071479A1 (en) Microspheres
WO2008027488A3 (en) Absorbent articles comprising polyamine-coated superabsorbent polymers
WO2006096546A3 (en) Biocompatible implant device
WO2007030545A3 (en) Biodegradable microparticle pharmaceutical formulations exhibiting improved release rates